[High macrolides and fluoroquinolones resistance rate in Mycoplasma genitalium in southern Tenerife]. / Elevada tasa de resistencia a macrólidos y fluoroquinolonas en Mycoplasma genitalium en el área sur de Tenerife.

OBJECTIVE: Mycoplasma genitalium (MG) is a recognized sexually transmitted pathogen. Increasing resistance to main lines of treatment (macrolides and quinolones) justifies a genetic study of mutations to improve cure rates. METHODS: A total of 8,508 samples from April 2018 to July 2022 were processed using AllplexTM STI Essential Assay. In MG positive cases 23S rRNA V domain, gyrA and parC genes were studied. Mutations detected were checked to assess their clinical significance and medical records were reviewed to obtain demographic and treatment information. RESULTS: Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented mutations to macrolides (30.43%). Most common was A2059G (18.48%). For quinolones, 5 patients (5.43%) had clinically relevant mutations in parC gene. Of note was a patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative. CONCLUSIONS: High rate of resistance in our environment evidences the need for targeted therapy by genotypic study of macrolide resistance, supported by the detection of mutations in parC and gyrA to predict quinolones susceptibility and the use of TOC to evaluate treatment response.

Subcellular distribution of pyroglutamyl-peptidase I activity in the developing rat cerebellum.

In this work we analyzed the activity of pyroglutamyl (pGlu)-peptidase I in several subcellular fractions of the rat cerebellum during its development. The aim of this study is to determine if there is a developmental redistribution of this enzyme activity and if this fact could indicate changes in the role of the enzyme as age progresses. Results show that pGlu-peptidase I is widely distributed, but not homogeneously, in all the subcellular fractions that were studied, in both soluble and particulate forms. Significantly the distribution of the enzyme changes with development. Thus, in the soluble synaptosomal fraction, the pGlu-peptidase I activity is low until PD9 and the activity increases significantly from PD9 to PD15, when it reaches adult levels. In contrast, in the cytosolic fraction, the pGlu-peptidase I activity is high from fetal day 22 to postnatal day 6, and then decreases significantly until postnatal day 90.